System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Andreas Mackensen is an expert in Hematology at Universitätsklinikum Erlangen (Germany). Andreas Mackensen has authored 420 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 6 of them ongoing. SLR score: 1,677 (community average: 125). How the SLR is computed.

LeadR Profile

Andreas Mackensen Universitätsklinikum Erlangen Germany
1 677 ScienceLeadR Reputation 1677

Unlock

Register Login
Network Map

Hematology

Subspecialties: Immunology - Oncology - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1991 - 2026
Source: PubMed

Center for Cancer Research

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 420

Citations

Citations: 20 904 1st author: 25 Last author: 49 Unique author: 0

Main journals

Blood 87
Cancer Immunol Immunother 14
Cancer Res 13
Leukemia 11
Ann Rheum Dis 9

Best Journals

Nat Med 8
Lancet 5
N Engl J Med 5

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Correction: Novel PE-DT-fusion toxin enhances internalization and target-dependently restores the cytotoxicity of recombinant immunotoxins.
PMID 42769319 — immunotoxins, diphtheria toxin		Front Pharmacol20260
Novel PE-DT-fusion toxin enhances internalization and target-dependently restores the cytotoxicity of recombinant immunotoxins.
PMID 42666587 — cells, immunotoxins, diphtheria toxin		Front Pharmacol20260
Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland - part II - expert based recommendations for surveillance and management of side-effects.
PMID 42658895 — muscular atrophy, genes, safety, atrophy, neuromuscular diseases, work, therapeutics, muscular atrophy, spinal, spine		J Neuromuscul Dis20260
Pregnancies in Patients with Autoimmune Disease Receiving CAR T-Cell Therapy.
PMID 42526043 — cells, pregnancy, autoimmune diseases, therapeutics, t-lymphocytes, car-t cell		N Engl J Med Top journal20260
Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells.
PMID 42177178 — skin, cells, sclerosis, therapeutics, tissues, scleroderma, systemic, car-t cell		Nat Commun20260

Clinical Studies 16

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 5
Phase 1/Phase 2 4
Phase 1 3
N/A 2
Phase 2 2

By status:

Recruiting 6
Completed 5
Active not recruiting 2
Terminated 2
Unknown 1

By type:

Interventional 16

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 0
multicentric5to9 6
multicentricup10 5

Main Topics

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Social Prescriptions and Micro Learning to Improve Care for Cancer Patients and Their Support Persons
NCT07788729 — pilots, lung, hematologic neoplasms, melanoma, neoplasms, prescriptions, lung neoplasms, work, colorectal neoplasms, learning		N/ARecruiting2026
A phase I safety dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers
2022-501725-21-00 — sarcoma, ewing, safety, breast neoplasms, neoplasms, sarcoma, breast, neuroblastoma, osteosarcoma		Phase 1Recruiting2024
Long term follow up of patients treated with GD2IL18CART
2025-521497-34-00 — sarcoma, ewing, breast neoplasms, neoplasms, sarcoma, breast, neuroblastoma, osteosarcoma		Phase 1Recruiting2025
Long Term Follow up of Patients Treated with Miltenyi Cell and Gene Therapies
2022-501648-14-00 — cells, genes, hodgkin disease, lymphoma, melanoma, leukemia, lymphocytic, chronic, b-cell, leukemia, lymphoma, non-hodgkin, therapeutics, b-lymphocytes		Phase 1/Phase 2Recruiting2024
CAR T Cells in Systemic B Cell Mediated Autoimmune Disease
NCT06347718 — dermatomyositis, cells, sclerosis, lupus erythematosus, systemic, polymyositis, autoimmune diseases, therapeutics, t-lymphocytes, b-lymphocytes, scleroderma, systemic, car-t cell		Phase 1/Phase 2Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS